Claims for Patent: 7,300,644

Summary for Patent: 7,300,644

Title:	Targeted combination immunotherapy
Abstract:	The present invention is directed to methods for treating cancer wherein more than one therapeutic agent is used, with each of the therapeutic agents having different tumor-killing capabilities, and wherein the therapeutic agents are delivered to the tumor sites using combined targeting and pre-targeting methods. The methods of the present invention achieve good tumor to non-tumor ratios of the therapeutic agents, and are effective for cancer therapy.
Inventor(s):	Griffiths; Gary L. (Morristown, NJ), Hansen; Hans J. (Slidell, LA), Goldenberg; David M. (Mendham, NJ)
Assignee:	Immunomedics, Inc. (Morris Plains, NJ)
Application Number:	10/361,026
Patent Claims:	1. A method for treating a patient with cancer comprising: (A) delivering a first conjugate comprising a multispecific antibody or antibody fragment and a first anti-cancer agent, wherein said multispecific antibody or antibody fragment binds to (i) at least one marker substance selected from the group consisting of carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), CD20, colon-specific antigen-p (CSAp), HLA-DR, human chorionic gonadrotropin, prostatic acid phosphatase (PAP), mammary tumor-associated glycoprotein, ovarian cystadenocarcinoma-associated antigen, ovarian tumor specific antigen, cervical cancer antigen, cytoplasmic melanoma associated antigen, melanoma cell surface antigen, breast cancer cell surface antigen, lung cancer cell surface antigen, colorectal cancer cell surface antigen, gastric cancer cell surface antigen, pancreatic cancer cell surface antigen, glioma cell surface antigen, common sarcomal cell surface antigen, gastrointestinal cancer cell surface antigen, brain tumor cell surface antigen, esophageal cancer cell surface antigen, common epithelial cancer cell surface antigen, osteosarcoma cell surface antigen, fibrosarcoma cell surface antigen, urinary bladder cancer cell surface antigen, prostatic cancer cell surface antigen, renal cancer cell surface antigen, ovarian cancer cell surface antigen, testicular cancer cell surface antigen, endometrial cancer cell surface antigen, Hodgkin's disease cell surface antigen, lymphoma cell surface antigen, leukemic cell surface antigen and trophoblastic tumor cell surface antigen, said cancer selected from the group consisting of a carcinoma, sarcoma, glioma, lymphoma, leukemia, melanoma and myeloma; and (ii) a first hapten; (B) optionally, administering a clearing agent; (C) delivering a second conjugate comprising a second hapten wherein said second hapten crosslinks to more than one multispecific antibodies or antibody fragments to increase cellular internalization, and a second anti-cancer agent, wherein said second anti-cancer agent comprises a drug-polymer conjugate; and (D) inducing said cellular internalization of said multi-specific antibody or antibody fragment. 2. The method of claim 1, wherein said multispecific antibody or antibody fragment binds to a first marker as recited in claim 1 and a second marker as recited in claim 1, wherein said second marker is different from said first marker. 3. The method of claim 1, wherein said multispecific antibody or antibody fragment binds to a first epitope and a second epitope on a marker as recited in claim 1, wherein said first epitope is different from said second epitope. 4. The method of claim 1, wherein said multispecific antibody or antibody fragment is a chimeric multispecific antibody or antibody fragment. 5. The method of claim 1, wherein said multispecific antibody or antibody fragment is a humanized multispecific antibody or antibody fragment. 6. The method of claim 1, wherein said multispecific antibody or antibody fragment is a fusion protein. 7. The method of claim 6, wherein said fusion protein is a bispecific fusion protein. 8. The method of claim 7, wherein said bispecific fusion protein comprises a scFv fragment and a Fab fragment, wherein said scFv fragment comprises one binding site for a first marker substance and said Fab fragment comprises one binding site for a second marker substance. 9. The method of claim 7, wherein said bispecific fusion protein comprises an IgG and two scFv fragments, wherein said IgG comprises two binding sites for a first marker substance, and said two scFv fragments comprises two binding sites for a second marker substance. 10. The method of claim 1, wherein each conjugate is generated by recombinant technology. 11. The method of claim 1, wherein the second conjugate comprises HSG (histamine-succinyl-glycine).

Details for Patent 7,300,644

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	March 13, 1924	7,300,644	2023-02-10
Sanofi-aventis U.s. Llc	ZALTRAP	ziv-aflibercept	Injection	125418	August 03, 2012	7,300,644	2023-02-10